載入中
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.
前收盤價
US$9.05
+US$0.04 · +0.44%
盤中時間採用ET。市場資料可能有所延遲。
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.
日內區間
目前US$9.05
52週區間
目前US$9.05
盤中時間採用ET。市場資料可能有所延遲。
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.
日內區間
目前US$9.05
52週區間
目前US$9.05
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 4376.6萬 USD | 634.4萬 USD | — | — | — |
| 銷貨成本 | 154.1萬 USD | — | — | — | 149.9萬 USD |
| 毛利 | 4222.5萬 USD | 634.4萬 USD | — | — | −149.9萬 USD |
| 研究與開發 | 5603.9萬 USD | 4121.1萬 USD | 5213.6萬 USD | 5920.1萬 USD | 5118.8萬 USD |
| 銷售、一般及管理費用 | 2970.9萬 USD | 2477.8萬 USD | 2699.7萬 USD | 2994.8萬 USD | 2235.7萬 USD |
| 營業費用 | 8420.7萬 USD | 6692.6萬 USD | 7913.3萬 USD | 8914.9萬 USD | 7354.5萬 USD |
| 利息收入 | 340萬 USD | — | — | — | 600 USD |
| 利息支出 | — | 10萬 USD | — | — | 60萬 USD |
| 折舊和攤銷 | 154.1萬 USD | 164.4萬 USD | 190萬 USD | 184.7萬 USD | 149.9萬 USD |
| 營業利益 | −4198.2萬 USD | −6058.2萬 USD | −7913.3萬 USD | −8914.9萬 USD | −7504.4萬 USD |
| 淨利 | −3503.6萬 USD | −5824.1萬 USD | −7640.4萬 USD | −8822.2萬 USD | −7580萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$98.00
上漲空間 982.87%評級樣本有限，僅3項
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年3月16日 | 1:14 | — | — |
已生效 2026年3月16日
1:14
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI127.48萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF49.47萬0.00%954億 USD0.05%US$235+0.80%
iShares Micro-Cap ETFIWC10.6萬0.01%13.17億 USD0.60%US$183+0.11%
U.S. Vector Equity Portfolio ETF Class SharesDXUV1.36萬0.00%61.81億 USD0.26%US$68.28+0.25%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR1.01萬0.00%455.91億 USD0.17%US$84.44+0.44%
Dimensional - US Core Equity 2 ETFDFAC2288.540.00%885.96億 USD0.21%US$45.33+0.49%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCU.S. Vector Equity Portfolio ETF Class SharesDXUVU.S. Core Equity 1 Portfolio ETF Class SharesDCORDimensional - US Core Equity 2 ETFDFACAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
